Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.75 |
| ▸ | MEN1 | O00255 | 4/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5790269 | 0.82 | POLB (0.79) | MAPTALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL20657500 | 0.82 | KMT2A (0.67) | MAPTALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL11793140 | 0.79 | CA1 (0.85) | MAPTALDH1A1KMT2AMEN1CA1 | |
| SCHEMBL540915 | 0.79 | CA1 (0.85) | MAPTALDH1A1KMT2AMEN1CA1 | |
| SCHEMBL19648927 | 0.78 | MAPT (0.50) | MAPTALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL20631 | 0.78 | MAPT (0.61) | MAPTALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL31145782 | 0.77 | KMT2A (0.72) | MAPTALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL10827903 | 0.77 | ALDH1A1 (0.62) | MAPTALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL20631313 | 0.76 | LMNA (0.61) | MAPTALDH1A1KMT2AMEN1USP2 | |
| Hydrochloric Acid SCHEMBL16209945 | 0.76 | MAPT (0.65) | MAPTALDH1A1KMT2AMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134859-A1 | PPAR-gamma modulator | SANKYO COMPANY, LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1277729-A1 | PPAR (GAMMA) MODULATORS | Sankyo Company, Limited (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134859-A1 | PPAR-gamma modulator | PPARG, PPARA, PPARD | MAPT 4391/4885ALDH1A1 583/4885KMT2A 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.